The Recipient Eligibility (2500) Form must be completed for recipients who are eligible for an open study.
For HCT, this form will come due after Pre-TED (2400) and Disease Classification (2402) forms are completed and The Pre-TED reports an eligible drug in Specify if the recipient received the following (at any time prior to HCT / infusion).
For cellular therapy, this form will come due if the product reported on the Pre-CTED (4000) form has an open study, and an eligible disease is reported on the Disease Classification (2402) form.
The Recipient Eligibility (2500) Form focuses on additional data necessary to determine study eligibility.
Links to sections of form:
Q1-2: Mogamulizumab
Q3-4: Cellular Therapy Studies
Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
To reference the historical Manual Change History for this form, review the retired manual section on the Retired Forms Manual webpage.
Section Updates:
| Date of Change | Manual Section | Add/Remove/Modify | Description |
|---|---|---|---|
| 1/23/2026 | 2500: Recipient Eligibility | Add | Version 1 of the Recipient Eligibility section of the Forms Instructions Manual released. Version 1 corresponds to revision 5 of the Form 2500. |
Need more help with this?
Don’t hesitate to contact us here.